Sutro Biopharma develops next-generation antibody-drug conjugates for oncology through a cell-free protein engineering platform. Recurring company news covers single- and dual-payload ADC design, pipeline programs such as STRO-004, STRO-006 and STRO-227, and preclinical data across tissue factor, ITGB6 and PTK7-targeting programs.
Updates also address clinical and regulatory disclosures, research and development collaborations, operating results, financing activity, equity compensation matters, investor and scientific conference participation, and Nasdaq listing compliance. The coverage reflects Sutro’s focus on site-specific ADCs for solid tumors and other cancer indications with limited treatment options.
Sutro Biopharma (NASDAQ: STRO) announced its participation in the 17th Annual World ADC Conference, taking place October 12–15, 2026, in San Diego. Presentations will cover the early clinical safety and pharmacokinetic profile—how a drug moves through the body—of STRO-004, preclinical findings on STRO-006, and preclinical characterization of STRO-227, its first wholly owned antibody drug conjugate carrying two payloads. Sutro scientists will also participate in discussions about payload combinations, drug resistance, and development and manufacturing needs. Presentation content will be available after the event in the Scientific Publications section of Sutro’s website.
Sutro Biopharma (STRO) appointed Lucas Donigian senior vice president of business development, effective September 28, 2026.
Donigian has more than 20 years of biotechnology experience and previously led business development and licensing at Zymeworks. Oncology partnerships he worked on before joining Sutro, including those involving antibody-drug conjugates, had an aggregate deal value of over $2 billion; they are not new Sutro agreements. Sutro granted him options to buy 25,000 common shares and 1,750 restricted stock units under its equity inducement plan. Both awards require continued service to vest.
Sutro is advancing STRO-006 in the clinic. The company aims to submit an investigational new drug application for STRO-227 this year and expects data from STRO-006 and STRO-227 next year.
Sutro Biopharma (NASDAQ: STRO) reported second quarter 2026 revenue of $9.8 million, down from $63.7 million a year earlier, and a net loss of $38.5 million ($2.33 per share). Total R&D and G&A expenses declined to $39.5 million from $48.7 million.
Cash, cash equivalents and marketable securities were $164.3 million as of June 30, 2026; the company expects this to fund operations into at least the second quarter of 2028. Sutro highlighted early data from its STRO-004 Phase 1 STRIVE-01 study, with multiple partial responses across three tumor types, a favorable tolerability profile with a 6% AE-related discontinuation rate, and PK consistent with preclinical data. STRO-006 remains on track to start Phase 1 in the third quarter of 2026, STRO-227 is expected to file an IND in 2026, and Astellas’ second dual-payload iADC program is anticipated to enter the clinic in the second half of 2026.
Sutro Biopharma (NASDAQ: STRO) reported Q1 2026 results and pipeline progress. Revenue was $14.5 million and R&D plus G&A expenses were $44.1 million. Cash, cash equivalents and marketable securities totaled $202.6 million, plus $110.0 million recent equity proceeds, extending cash runway into at least Q2 2028.
The company advanced ADC candidates STRO-004, STRO-006 and STRO-227, with initial STRO-004 Phase 1 data expected mid‑2026 and IND submissions for STRO-006 and STRO-227 planned in 2026. Under its Astellas collaboration, a TROP2 dual‑payload iADC entered the clinic, triggering a $10 million milestone. Sutro also closed its luvelta program.
Sutro Biopharma (NASDAQ: STRO) reported preclinical AACR 2026 results showing next-generation single- and dual-payload ADCs with robust antitumor activity across multiple solid tumor models.
Key points: STRO-004 showed tumor control at a single 5 mg/kg dose and HNSTD of 50 mg/kg; STRO-006 and STRO-227 demonstrated dose-dependent activity; STRO-227 IND planned for late 2026; STRO-004 Phase 1 results expected mid-2026. Partner Astellas’ TROP2 iADC ASP2998 is already dosing in clinic.
Sutro Biopharma (NASDAQ: STRO) reported full-year 2025 results and program updates. Key financials: $141.4M cash at December 31, 2025 and $102.5M 2025 revenue (vs. $62.0M in 2024). A $110.0M equity offering extends runway into at least Q2 2028.
Clinical highlights: three cohorts dosed in the Phase 1 STRO-004 program with initial data expected mid-2026; STRO-227 IND targeted for 2026; an Astellas-partnered iADC has entered the clinic, triggering near-term milestones.
Sutro Biopharma (NASDAQ: STRO) announced management participation in multiple investor conferences in early March 2026, including TD Cowen, Leerink Partners, Citizens Life Sciences, and Barclays.
Webcasts of fireside chats at TD Cowen and Citizens will be accessible via the company’s Events & Presentations page, with archived replays available for at least 30 days.
Sutro Biopharma (NASDAQ: STRO) will participate at the 16th World ADC London Summit in London, UK, February 23-26, 2026. Senior scientist Hans-Peter Gerber, Ph.D. will join panel discussions and present on dual-payload ADC efficacy and safety.
According to the company, plenary content will be posted in Sutro's Scientific Publications section after the event.
Sutro Biopharma (Nasdaq: STRO) priced an underwritten offering of 7,868,383 common shares at $13.98 per share, expected to raise approximately $110.0 million in gross proceeds before fees. The offering is expected to close on or about February 11, 2026.
Proceeds, together with existing cash and marketable securities, are intended primarily for general corporate purposes, including funding research, clinical and process development, manufacturing, working capital, and potential acquisitions or investments. Joint bookrunning managers include Leerink Partners, TD Cowen and LifeSci Capital.
Sutro Biopharma (NASDAQ: STRO) announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 11:15 AM PT / 2:15 PM ET in San Francisco.
A live webcast will be accessible via the Events & Presentations page of the Investor Relations section at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.